I am pleased with the overall strong performance of our business in the third quarter, particularly the dynamic growth of Pharmaceuticals.

If you can't find the human resources in Europe you go elsewhere. As a European, I'm concerned for Europe.

At present, no collaboration has been discussed with Roche management, although we hope that over time we will be able to explore areas of collaboration.

We first want to fix the quality and quantity problems which are at hand.

We are entering an exciting field with vaccines. Chiron has a fair share of challenges but I believe we can help them in solving those.

We are confident of delivering in 2006 another year of dynamic growth with record sales and earnings.

Litigation is potentially much larger when you vaccinate healthy people.

Market growth in 2006 will slow down somewhat. I expect that we will be able to continue to gain market share.

Looking ahead, we anticipate a somewhat softer third quarter and, again, a more dynamic fourth quarter resulting in mid-single-digit sales growth... and solid operating growth for the full year,

Our plan is to turn around the Chiron vaccines business,